| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-09-02 | King-Jones Heidy | officer | Option exercise | 400 | $14.50 | $6K |
| 2026-09-02 | King-Jones Heidy | officer | Sale | 400 | $90.00 | $36K |
| 2026-09-02 | Burrows Scott L | officer | Sale | 18,232 | $89.35 | $1.63M |
| 2026-09-01 | King-Jones Heidy | officer | Option exercise | 27,999 | $14.50 | $406K |
| 2026-09-01 | King-Jones Heidy | officer | Sale | 4,845 | $86.40 | $419K |
| 2026-09-01 | King-Jones Heidy | officer | Sale | 16,548 | $87.20 | $1.44M |
| 2026-09-01 | King-Jones Heidy | officer | Sale | 6,206 | $88.17 | $547K |
| 2026-09-01 | King-Jones Heidy | officer | Sale | 400 | $89.38 | $36K |
| 2026-09-01 | Burrows Scott L | officer | Option exercise | 7,500 | $14.50 | $109K |
| 2026-09-01 | Burrows Scott L | officer | Sale | 900 | $86.25 | $78K |
| 2026-09-01 | Burrows Scott L | officer | Sale | 4,384 | $87.11 | $382K |
| 2026-09-01 | Burrows Scott L | officer | Sale | 2,016 | $88.03 | $177K |
| 2026-09-01 | Burrows Scott L | officer | Sale | 200 | $89.04 | $18K |
| 2026-09-01 | Turtle Cameron | director, officer | Sale | 2,500 | $86.36 | $216K |
| 2026-09-01 | Turtle Cameron | director, officer | Sale | 8,400 | $87.15 | $732K |
| 2026-09-01 | Turtle Cameron | director, officer | Sale | 3,700 | $88.06 | $326K |
| 2026-09-01 | Turtle Cameron | director, officer | Sale | 400 | $89.07 | $36K |
| 2026-08-07 | Albers Jeffrey W. | director | Option exercise | 5,000 | $10.39 | $52K |
| 2026-08-07 | Albers Jeffrey W. | director | Sale | 5,000 | $104.47 | $522K |
| 2026-08-07 | Albers Jeffrey W. | director | Sale | 8,000 | $104.38 | $835K |
| 2026-08-07 | Albers Jeffrey W. | director | Sale | 10,000 | $104.68 | $1.05M |
| 2026-08-03 | Burrows Scott L | officer | Option exercise | 7,500 | $14.50 | $109K |
| 2026-08-03 | Burrows Scott L | officer | Sale | 5,100 | $95.21 | $486K |
| 2026-08-03 | Burrows Scott L | officer | Sale | 2,300 | $96.30 | $221K |
| 2026-08-03 | Burrows Scott L | officer | Sale | 100 | $97.10 | $10K |
| Filed | Form | Filer | Stake | Shares | |
|---|---|---|---|---|---|
| 2026-06-23 | SCHEDULE 13D/A | Fairmount Funds Management LLC | — | 8,835,440 | view → |
| 2023-12-11 | SC | Fairmount Funds Management LLC | — | — | view → |
| 2022-02-10 | SC | BAKER BROS. ADVISORS LP | — | — | view → |
| Filed | Form | Issuer | Stake | Shares | |
|---|---|---|---|---|---|
| 2026-08-11 | SCHEDULE 13D/A | Replimune Group, Inc. | 11.80% | 11,075,336 | view → |
| 2026-07-16 | SCHEDULE 13D/A | Celcuity Inc. | 9.99% | 4,877,963 | view → |
| 2026-07-16 | SCHEDULE 13G | Celcuity Inc. | — | — | view → |
| 2026-06-15 | SCHEDULE 13D/A | BeOne Medicines Ltd. BEIGF | 8.00% | 115,457,154 | view → |
| 2026-05-26 | SCHEDULE 13D/A | Kiniksa Pharmaceuticals International, plc KNSA | 7.00% | 3,231,181 | view → |
| 2026-05-11 | SCHEDULE 13D/A | Incyte Corp INCY | — | 30,865,077 | view → |
| 2025-06-30 | SCHEDULE | Kymera Therapeutics, Inc. KYMR | 9.50% | 6,666,540 | view → |
| 2024-10-08 | SC | Kiniksa Pharmaceuticals International, plc KNSA | — | — | view → |
| 2024-06-14 | SC | INCYTE CORP INCY | — | — | view → |
| 2023-12-18 | SC | Seagen Inc. | — | — | view → |
| 2023-10-10 | SC | Neoleukin Therapeutics, Inc. NGNE | — | — | view → |
| 2023-10-05 | SC | MADRIGAL PHARMACEUTICALS, INC. MDGL | — | — | view → |
| 2023-07-19 | SC | Neoleukin Therapeutics, Inc. NGNE | — | — | view → |
| 2023-05-24 | SC | Prelude Therapeutics Inc PRLD | — | — | view → |
| 2023-05-24 | SC | ACADIA PHARMACEUTICALS INC ACAD | — | — | view → |
| 2023-05-03 | SC | Seagen Inc. | — | — | view → |
| 2023-03-15 | SC | INCYTE CORP INCY | — | — | view → |
| 2023-03-13 | SC | Seagen Inc. | — | — | view → |
| 2023-01-17 | SC | ACADIA PHARMACEUTICALS INC ACAD | — | — | view → |
| 2022-07-20 | SC | Immunocore Holdings plc IMCR | — | — | view → |
Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.
See pricing →